2366-1070

Oncology and Therapy

Springer-Verlag

View prefix report (10.1007)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 413 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact413 DOIs
2

Attach ORCID iDs across 186 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact186 DOIs
3

Add license metadata to 33 records

License metadata tells indexers and readers how each article may be reused.

Low impact33 DOIs

DOIs for this ISSN

Showing the top 5 of 413 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 DNA Mutations May Not Be the Cause of Cancer (10.1007/s40487-017-0047-1)
Abstract ORCID License
133.90 60
2 Health-Related Quality of Life of Patients with Acute Myeloi… (10.1007/s40487-016-0039-6)
Abstract ORCID License
122.51 42
3 EGFR Inhibitors and Cutaneous Complications: A Practical App… (10.1007/s40487-017-0050-6)
Abstract ORCID License
120.96 40
4 Panobinostat as Pan-deacetylase Inhibitor for the Treatment… (10.1007/s40487-016-0023-1)
Abstract ORCID License
120.15 39
5 Chordoma: The Quest for Better Treatment Options (10.1007/s40487-016-0016-0)
Abstract ORCID License
115.81 34
6 A Review of Fulvestrant in Breast Cancer (10.1007/s40487-017-0046-2)
Abstract License
112.76 179
7 Identifying and Targeting the Cause of Cancer is Needed to C… (10.1007/s40487-015-0015-6)
Abstract ORCID License
106.12 25
8 Cutaneous CD8+ Cytotoxic T-Cell Lymphoma Infiltrates: Clinic… (10.1007/s40487-016-0026-y)
Abstract ORCID License
97.58 19
9 Impact of CYP3A4*18 and CYP3A5*3 Polymorphisms on Imatinib M… (10.1007/s40487-016-0035-x)
Abstract ORCID License
97.58 19
10 Background and Current Treatment of Squamous Cell Carcinoma… (10.1007/s40487-016-0024-0)
Abstract ORCID License
95.91 18
11 Uveal Melanoma: A Review of the Literature (10.1007/s40487-018-0056-8)
Abstract ORCID
92.25 69
12 Intra-Abdominal and Abdominal Wall Desmoid Fibromatosis (10.1007/s40487-016-0017-z)
Abstract License
90.65 64
13 Real-World Treatment Patterns for Hormone Receptor-Positive,… (10.1007/s40487-016-0033-z)
Abstract ORCID License
90.31 15
14 Acute Promyelocytic Leukemia: A History over 60 Years—From t… (10.1007/s40487-018-0091-5)
Abstract ORCID
88.17 57
15 Current Status and Study Progress of Recombinant Human Endos… (10.1007/s40487-017-0055-1)
Abstract ORCID
87.79 56
16 Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lun… (10.1007/s40487-018-0064-8)
Abstract ORCID
85.38 50
17 Invasive Lobular Breast Cancer as a Distinct Disease: Implic… (10.1007/s40487-019-00105-0)
Abstract ORCID
84.95 49
18 Gender Differences and Outcomes in Melanoma Patients (10.1007/s40487-020-00109-1)
Abstract ORCID
84.95 49
19 Endocrine Therapy for Breast Cancer: A Model of Hormonal Man… (10.1007/s40487-018-0062-x)
Abstract ORCID
83.60 46
20 The Time Has Come for Targeted Therapies for AML: Lights and… (10.1007/s40487-019-00108-x)
Abstract ORCID
79.55 38
21 Recent Advances in the Management of Penile Cancer: A Contem… (10.1007/s40487-020-00135-z)
Abstract ORCID
79.55 38
22 Response to PD-1-Based Immunotherapy for Non-Small Cell Lung… (10.1007/s40487-021-00171-3)
Abstract ORCID
78.99 37
23 The Treatment of Non-Melanoma Skin Cancer with Image-Guided… (10.1007/s40487-021-00138-4)
Abstract ORCID
78.41 36
24 A Combination of Two Receptor Tyrosine Kinase Inhibitors, Ca… (10.1007/s40487-016-0031-1)
Abstract ORCID License
78.10 10
25 A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatmen… (10.1007/s40487-018-0058-6)
Abstract ORCID
75.26 31
26 A Review of Immune-Mediated Adverse Events in Melanoma (10.1007/s40487-019-0096-8)
Abstract ORCID
75.26 31
27 Liquid Chromatography–Mass Spectrometry/Mass Spectrometry An… (10.1007/s40487-016-0022-2)
Abstract ORCID License
75.00 9
28 Network Meta-analysis of Progression-Free Survival and Overa… (10.1007/s40487-016-0030-2)
Abstract ORCID License
75.00 9
29 Bone Marrow Necrosis in Newly Diagnosed Acute Leukemia: Two… (10.1007/s40487-017-0041-7)
Abstract ORCID License
75.00 9
30 Patient Perspectives on Health-Related Quality of Life in Di… (10.1007/s40487-021-00174-0)
Abstract ORCID
72.36 27
31 The Roles of Common Variation and Somatic Mutation in Cancer… (10.1007/s40487-018-0090-6)
Abstract ORCID
71.57 26
32 The Patient Perspective on Living with Acute Myeloid Leukemi… (10.1007/s40487-016-0029-8)
Abstract ORCID
69.90 24
33 Current Challenges Faced by Cancer Clinical Trials in Addres… (10.1007/s40487-021-00140-w)
Abstract ORCID
69.90 24
34 Health-Related Quality of Life as a Prognostic Measure of Cl… (10.1007/s40487-017-0042-6)
Abstract ORCID License
67.73 7
35 The Readability of Online Patient Resources for Skin Cancer… (10.1007/s40487-017-0051-5)
Abstract License
65.05 19
36 Expression and Prognostic Significance of Stem Cell Marker C… (10.1007/s40487-022-00205-4)
Abstract ORCID
63.94 18
37 Factors Impacting Treatment Choice in the First-Line Treatme… (10.1007/s40487-016-0020-4)
Abstract ORCID License
63.38 6
38 Switching from an LHRH Antagonist to an LHRH Agonist: A Case… (10.1007/s40487-017-0040-8)
Abstract ORCID License
63.38 6
39 Second-line Treatments for Advanced Gastric Cancer: A Networ… (10.1007/s40487-017-0048-0)
Abstract ORCID License
63.38 6
40 64Cu-DOTATOC PET-CT in Patients with Neuroendocrine Tumors (10.1007/s40487-019-00104-1)
Abstract ORCID
62.76 17
41 Real-World Impact of Physician and Patient Discordance on He… (10.1007/s40487-019-0094-x)
Abstract ORCID
61.52 16
42 Early Relapse in First-Line Follicular Lymphoma: A Review of… (10.1007/s40487-021-00161-5)
Abstract ORCID
61.52 16
43 Exploratory Analysis Comparing Fosnetupitant Versus Fosaprep… (10.1007/s40487-022-00188-2)
Abstract ORCID
61.52 16
44 Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pa… (10.1007/s40487-021-00168-y)
Abstract
60.90 272
45 RET Rearrangement as a Predictor of Unresponsiveness to Immu… (10.1007/s40487-020-00116-2)
Abstract ORCID
60.21 15
46 Estimating the Impact of Delayed Access to Oncology Drugs on… (10.1007/s40487-022-00187-3)
Abstract ORCID
60.21 15
47 Real-World Outcomes of Belantamab Mafodotin for Relapsed/Ref… (10.1007/s40487-022-00212-5)
Abstract ORCID
60.21 15
48 Exploring the Potential of Ellagic Acid in Gastrointestinal… (10.1007/s40487-024-00296-1)
Abstract ORCID
60.21 15
49 What is the Definition of Cure in Non-small Cell Lung Cancer… (10.1007/s40487-021-00163-3)
Abstract ORCID
58.80 14
50 Epidemiology and Real-World Treatment of Incident Diffuse La… (10.1007/s40487-024-00265-8)
Abstract ORCID
58.80 14